Patel Sanjiv sold $980K of RLAY
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $20.33 ($0.98M total) on 2026-08-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the reported sale size, price, and post-transaction holdings; it does not include any new corporate event or performance metric.
Market read
Traders may briefly monitor for sentiment effects from insider selling, but the 10b5-1 structure reduces the likelihood of a fundamental read-through.
What to watch
The article does not disclose any concurrent buy/sell by other insiders, changes in guidance, or new clinical/regulatory milestones, limiting inference.
Background
The article is a SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc. (RLAY).
Ticker impact
Relay Therapeutics CEO Patel Sanjiv sold 48,199 shares in an open-market transaction worth about $979,885.67 on 2026-08-17.
Near-term price impact is likely limited; any reaction would be sentiment-driven rather than fundamentals-driven.
The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, and it provides no new company-specific operational or financial information.
Market effects
Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or clinical changes.
None indicated.
None indicated.
Counterpoint
Insider sales can be interpreted as liquidity management rather than bearish information, especially when tied to a 10b5-1 plan.
Key entities
- issuerRelay Therapeutics, Inc.
Subject of the Form 4 insider sale by its President and CEO.
- insiderPatel Sanjiv
President and CEO who executed an open-market sale under a pre-arranged 10b5-1 plan.